{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:01:50Z","timestamp":1793282510245,"version":"4.5.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Tier I Canada Research Chair","award":["CRC-2017-00186"],"award-info":[{"award-number":["CRC-2017-00186"]}]},{"name":"National Heart Foundation Future Leader Fellowship","award":["107323"],"award-info":[{"award-number":["107323"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Statins are among the most widely prescribed medications in older individuals. Inconsistent data in humans suggest that statin medications may be associated with greater BMD and lower risk for osteoporosis. We identified 22\u2009393 individuals aged 40\u00a0yr and older undergoing initial (Visit 1) and repeat (Visit 2) TH BMD measurement within 1-10\u00a0yr total from DXA through the Manitoba BMD Program (February 28, 1999 to March 29, 2018). Linked medication records showed that 4119 (18.3%) of the study population were statin users at Visit 1 and 6667 (29.8%) were statin users at Visit 2. There was inconsistent and largely negative evidence for prior statin use affecting initial TH BMD measurement or BMD change during follow-up. Even among those with the greatest exposure (mean 5.1\u00a0yr of prior statin use with high adherence), the observed effects on covariate-adjusted initial TH BMD or annualized change in TH BMD change did not show clinically significant differences. In summary, this large observational analysis, which included both cross-sectional and longitudinal components, failed to detect a clinically meaningful benefit of statin exposure on bone density, even when taken with high adherence over several years.<\/jats:p>","DOI":"10.1093\/jbmr\/zjaf077","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T08:20:36Z","timestamp":1748506836000},"page":"1045-1051","source":"Crossref","is-referenced-by-count":6,"title":["Cross-sectional and longitudinal associations between statin use and bone density: the Manitoba BMD registry"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1056-1691","authenticated-orcid":false,"given":"William D","family":"Leslie","sequence":"first","affiliation":[{"name":"University of Manitoba , Rady College of Medicine, Winnipeg , MB R3E 0W2,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Zarzour","sequence":"additional","affiliation":[{"name":"University of Manitoba , Rady College of Medicine, Winnipeg , MB R3E 0W2,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9905-461X","authenticated-orcid":false,"given":"Neil","family":"Binkley","sequence":"additional","affiliation":[{"name":"University of Wisconsin , Department of Medicine, Madison , WI 53705,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-492X","authenticated-orcid":false,"given":"Suzanne N","family":"Morin","sequence":"additional","affiliation":[{"name":"McGill University , Department of Medicine, Montreal , QU H4A 3S5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9329-0750","authenticated-orcid":false,"given":"John T","family":"Schousboe","sequence":"additional","affiliation":[{"name":"Park Nicollet Clinic and HealthPartners Institute, HealthPartners , Minneapolis , MN 55416,","place":["United States"]},{"name":"University of Minnesota , Division of Health Policy and Management, Minneapolis , MN 55455,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"8","key":"2025090306420878500_ref1","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025090306420878500_ref2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bone.2007.11.001","article-title":"A reference standard for the description of osteoporosis","volume":"42","author":"Kanis","year":"2008","journal-title":"Bone"},{"issue":"10169","key":"2025090306420878500_ref3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"2025090306420878500_ref4","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025090306420878500_ref5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"17","author":"Gregson","year":"2022","journal-title":"Arch Osteoporos"},{"issue":"39","key":"2025090306420878500_ref6","doi-asserted-by":"publisher","first-page":"E1333","DOI":"10.1503\/cmaj.221647","article-title":"Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update","volume":"195","author":"Morin","year":"2023","journal-title":"CMAJ"},{"key":"2025090306420878500_ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.27154","article-title":"Screening for osteoporosis to prevent fractures: US preventive services task force recommendation statement","volume":"333","author":"","year":"2025","journal-title":"JAMA"},{"issue":"5446","key":"2025090306420878500_ref8","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.286.5446.1946","article-title":"Stimulation of bone formation in vitro and in rodents by statins","volume":"286","author":"Mundy","year":"1999","journal-title":"Science"},{"issue":"5","key":"2025090306420878500_ref9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00223-001-2027-5","article-title":"Statin given perorally to adult rats increases cancellous bone mass and compressive strength","volume":"69","author":"Oxlund","year":"2001","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"2025090306420878500_ref10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1600-0501.2007.01508.x","article-title":"Topical application of statin affects bone healing around implants","volume":"19","author":"Moriyama","year":"2008","journal-title":"Clin Oral Implants Res"},{"issue":"11","key":"2025090306420878500_ref11","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1055\/s-0028-1082051","article-title":"Statin suppresses apoptosis in osteoblastic cells: role of transforming growth factor-beta-Smad3 pathway","volume":"40","author":"Kaji","year":"2008","journal-title":"Horm Metab Res"},{"issue":"3","key":"2025090306420878500_ref12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.tripleo.2008.07.013","article-title":"Local application of statin promotes bone repair through the suppression of osteoclasts and the enhancement of osteoblasts at bone-healing sites in rats","volume":"107","author":"Ayukawa","year":"2009","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"15","key":"2025090306420878500_ref13","first-page":"1921","article-title":"Statin drugs and the risk of fracture","volume":"284","author":"Pedersen","year":"2000","journal-title":"JAMA"},{"issue":"2","key":"2025090306420878500_ref14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jamainternmed.2014.6388","article-title":"Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial","volume":"175","author":"Pe\u00f1a","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"5","key":"2025090306420878500_ref15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/archinte.162.5.537","article-title":"Statin use, bone mineral density, and fracture risk: Geelong osteoporosis study","volume":"162","author":"Pasco","year":"2002","journal-title":"Arch Intern Med"},{"issue":"7","key":"2025090306420878500_ref16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s001980200070","article-title":"Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women","volume":"13","author":"Sirola","year":"2002","journal-title":"Osteoporos Int"},{"issue":"2","key":"2025090306420878500_ref17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.7326\/0003-4819-139-2-200307150-00009","article-title":"Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative observational study","volume":"139","author":"LaCroix","year":"2003","journal-title":"Ann Intern Med"},{"issue":"10","key":"2025090306420878500_ref18","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1046\/j.1600-6143.2003.00209.x","article-title":"Statin use and bone mineral density in renal transplant recipients","volume":"3","author":"Prasad","year":"2003","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"4","key":"2025090306420878500_ref19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/pds.984","article-title":"Statin lipid-lowering drugs and bone mineral density","volume":"14","author":"Solomon","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"2025090306420878500_ref20","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1136\/annrheumdis-2019-215714","article-title":"Diagnosis of osteoporosis in statin-treated patients is dose-dependent","volume":"78","author":"Leutner","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"2025090306420878500_ref21","doi-asserted-by":"publisher","first-page":"11902","DOI":"10.3390\/ijerph182211902","article-title":"Association between osteoporosis and previous statin use: a nested case-control study","volume":"18","author":"Kim","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"2025090306420878500_ref22","first-page":"1137","article-title":"HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients","volume":"85","author":"Chung","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"2025090306420878500_ref23","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1001\/archinte.160.18.2865","article-title":"Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes","volume":"160","author":"Wada","year":"2000","journal-title":"Arch Intern Med"},{"issue":"2","key":"2025090306420878500_ref24","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.asjsur.2024.08.060","article-title":"Relationship between statin drugs and bone density: a drug target-mediated Mendelian randomization study","volume":"48","author":"Huo","year":"2024","journal-title":"Asian J Surg"},{"issue":"2","key":"2025090306420878500_ref25","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s10787-024-01441-y","article-title":"Association of statin use with osteoporosis risk: a drug-targeted Mendelian randomization study","volume":"32","author":"Ren","year":"2024","journal-title":"Inflammopharmacology"},{"issue":"1","key":"2025090306420878500_ref26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/0141076814562718","article-title":"The environment and disease: association or causation? 1965","volume":"108","author":"Hill","year":"2015","journal-title":"J R Soc Med"},{"issue":"3","key":"2025090306420878500_ref27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1385\/JCD:6:3:275","article-title":"Establishing a regional bone density program: lessons from the Manitoba experience","volume":"6","author":"Leslie","year":"2003","journal-title":"J Clin Densitom"},{"issue":"1","key":"2025090306420878500_ref28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1385\/JCD:8:1:025","article-title":"Construction and validation of a population-based bone densitometry database","volume":"8","author":"Leslie","year":"2005","journal-title":"J Clin Densitom"},{"issue":"11","key":"2025090306420878500_ref29","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1345\/aph.18117","article-title":"Validation of an electronic, population-based prescription database","volume":"32","author":"Kozyrskyj","year":"1998","journal-title":"Ann Pharmacother"},{"issue":"6 Suppl","key":"2025090306420878500_ref30","doi-asserted-by":"publisher","first-page":"JS42","DOI":"10.1097\/00005650-199906001-00008","article-title":"The population's use of pharmaceuticals","volume":"37","author":"Metge","year":"1999","journal-title":"Med Care"},{"issue":"3","key":"2025090306420878500_ref31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/jbmr\/zjae201","article-title":"The relationship between baseline BMD and fracture incidence in the placebo groups of RCTs using individual patient data from the FNIH-ASBMR-SABRE project","volume":"40","author":"Schini","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2025090306420878500_ref32","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1093\/jbmr\/zjae126","article-title":"The relationship between treatment-related changes in total hip BMD measured after 12, 18, and 24 mo and fracture risk reduction in osteoporosis clinical trials: the FNIH-ASBMR-SABRE project","volume":"39","author":"Vilaca","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025090306420878500_ref33","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025090306420878500_ref34","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00198-019-04975-y","article-title":"Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study","volume":"30","author":"Leslie","year":"2019","journal-title":"Osteoporos Int"},{"issue":"5","key":"2025090306420878500_ref35","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s001980050093","article-title":"Updated data on proximal femur bone mineral levels of US adults","volume":"8","author":"Looker","year":"1998","journal-title":"Osteoporos Int"},{"issue":"4","key":"2025090306420878500_ref36","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jocd.2013.08.001","article-title":"2013 International Society for Clinical Densitometry Position Development Conference: task force on normative databases","volume":"16","author":"Watts","year":"2013","journal-title":"J Clin Densitom"},{"issue":"3","key":"2025090306420878500_ref37","doi-asserted-by":"publisher","first-page":"101493","DOI":"10.1016\/j.jocd.2024.101493","article-title":"Assessing change in spine bone density from different numbers and combinations of lumbar vertebrae: the Manitoba BMD registry","volume":"27","author":"Szalat","year":"2024","journal-title":"J Clin Densitom"},{"issue":"6","key":"2025090306420878500_ref38","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/jbmr.3682","article-title":"Accuracy of FRAX(R) in people with multiple sclerosis","volume":"34","author":"Bisson","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2025090306420878500_ref39","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/jbmr.3726","article-title":"Performance of FRAX in women with breast cancer initiating aromatase inhibitor therapy: a registry-based cohort study","volume":"34","author":"Leslie","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2025090306420878500_ref40","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2337\/diacare.19.8.807","article-title":"Incidence and prevalence of diabetes in Manitoba, 1986-1991","volume":"19","author":"Blanchard","year":"1996","journal-title":"Diabetes Care"},{"issue":"1","key":"2025090306420878500_ref41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.24095\/hpcdp.29.1.04","article-title":"Population-based data sources for chronic disease surveillance","volume":"29","author":"Lix","year":"2008","journal-title":"Chronic Dis Can"},{"issue":"1","key":"2025090306420878500_ref42","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bone.2013.01.044","article-title":"HMG-CoA reductase inhibitors (statins) and bone mineral density: a meta-analysis","volume":"54","author":"Liu","year":"2013","journal-title":"Bone"},{"issue":"5","key":"2025090306420878500_ref43","first-page":"8269","article-title":"Statin use and risk of fracture: a meta-analysis","volume":"8","author":"Jin","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"5","key":"2025090306420878500_ref44","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1507\/endocrj.EJ22-0512","article-title":"The effect of statins on bone turnover biomarkers: a systematic review and meta-analysis of randomized controlled trials","volume":"70","author":"Zhao","year":"2023","journal-title":"Endocr J"},{"issue":"3","key":"2025090306420878500_ref45","doi-asserted-by":"publisher","first-page":"591","DOI":"10.34172\/apb.2024.051","article-title":"The effect of statin therapy on bone metabolism markers and mineral density: aa GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials","volume":"14","author":"Arabi","year":"2024","journal-title":"Adv Pharm Bull"},{"issue":"1","key":"2025090306420878500_ref46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0165-6147(97)01147-4","article-title":"Hydrophilicity\/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors","volume":"19","author":"Hamelin","year":"1998","journal-title":"Trends Pharmacol Sci"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf077\/63397657\/zjaf077.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/9\/1045\/63397657\/zjaf077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/9\/1045\/63397657\/zjaf077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:42:14Z","timestamp":1756896134000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/40\/9\/1045\/8152720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,29]]},"published-print":{"date-parts":[[2025,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjaf077","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,29]]}}}